An FDA-Approved Tenofovir Alafenamide-Based Antiretroviral Therapy Reduces Biological Age in Healthy Adults: First Human Proof-of-Concept for Retrotransposon-Targeted Gerotherapeutics - PubMed
6 hours ago
- #Epigenetic Aging
- #Gerotherapeutics
- #Retrotransposons
- A preprint reports that a 12-week course of the FDA-approved antiretroviral regimen emtricitabine-tenofovir alafenamide (FTC/TAF) reduced measures of biological aging in healthy adults without HIV.
- Epigenetic clocks like DunedinPACE and PhenoAge showed significant decreases with FTC/TAF, alongside reductions in epigenetic proxies for inflammation such as IL-6, suggesting anti-aging effects.
- In contrast, a similar regimen using tenofovir disoproxil fumarate (FTC/TDF) did not show significant changes in aging markers, attributed to TAF's superior cellular pharmacology over TDF.
- This study provides the first human proof-of-concept for using retrotransposon-targeted therapies as gerotherapeutics, supporting further placebo-controlled trials with geroscience endpoints.